BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 10896269)

  • 1. Muscle autoantibodies in subgroups of myasthenia gravis patients.
    Romi F; Skeie GO; Aarli JA; Gilhus NE
    J Neurol; 2000 May; 247(5):369-75. PubMed ID: 10896269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The severity of myasthenia gravis correlates with the serum concentration of titin and ryanodine receptor antibodies.
    Romi F; Skeie GO; Aarli JA; Gilhus NE
    Arch Neurol; 2000 Nov; 57(11):1596-600. PubMed ID: 11074791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Titin and ryanodine receptor autoantibodies in dogs with thymoma and late-onset myasthenia gravis.
    Shelton GD; Skeie GO; Kass PH; Aarli JA
    Vet Immunol Immunopathol; 2001 Jan; 78(1):97-105. PubMed ID: 11182151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoantibodies in thymoma-associated myasthenia gravis with myositis or neuromyotonia.
    Mygland A; Vincent A; Newsom-Davis J; Kaminski H; Zorzato F; Agius M; Gilhus NE; Aarli JA
    Arch Neurol; 2000 Apr; 57(4):527-31. PubMed ID: 10768628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Titin and ryanodine receptor epitopes are expressed in cortical thymoma along with costimulatory molecules.
    Romi F; Bø L; Skeie GO; Myking A; Aarli JA; Gilhus NE
    J Neuroimmunol; 2002 Jul; 128(1-2):82-9. PubMed ID: 12098514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thymectomy and anti-muscle autoantibodies in late-onset myasthenia gravis.
    Romi F; Gilhus NE; Varhaug JE; Myking A; Skeie GO; Aarli JA
    Eur J Neurol; 2002 Jan; 9(1):55-61. PubMed ID: 11784377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement activation by titin and ryanodine receptor autoantibodies in myasthenia gravis. A study of IgG subclasses and clinical correlations.
    Romi F; Skeie GO; Vedeler C; Aarli JA; Zorzato F; Gilhus NE
    J Neuroimmunol; 2000 Nov; 111(1-2):169-76. PubMed ID: 11063835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease severity and outcome in thymoma myasthenia gravis: a long-term observation study.
    Romi F; Gilhus NE; Varhaug JE; Myking A; Aarli JA
    Eur J Neurol; 2003 Nov; 10(6):701-6. PubMed ID: 14641516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Titin and ryanodine receptor antibodies in myasthenia gravis.
    Skeie GO; Aarli JA; Gilhus NE
    Acta Neurol Scand Suppl; 2006; 183():19-23. PubMed ID: 16637922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myasthenia gravis sera containing antiryanodine receptor antibodies inhibit binding of [3H]-ryanodine to sarcoplasmic reticulum.
    Skeie GO; Lunde PK; Sejersted OM; Mygland A; Aarli JA; Gilhus NE
    Muscle Nerve; 1998 Mar; 21(3):329-35. PubMed ID: 9486861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoimmunity to ryanodine receptor and titin in myasthenia gravis is associated with GM allotypes.
    Skeie GO; Pandey JP; Aarli JA; Gilhus NE
    Autoimmunity; 1997; 26(2):111-6. PubMed ID: 9546812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Thymectomy and muscle antibodies in myasthenia gravis].
    Romi F; Gilhus NE; Aarli JA
    Tidsskr Nor Laegeforen; 2004 Mar; 124(5):629-31. PubMed ID: 15004605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thymectomy and antimuscle antibodies in nonthymomatous myasthenia gravis.
    Romi F; Gilhus NE; Varhaug JE; Myking A; Skeie GO; Aarli JA
    Ann N Y Acad Sci; 2003 Sep; 998():481-90. PubMed ID: 14592917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-titin and antiryanodine receptor antibodies in myasthenia gravis patients with thymoma.
    Baggi F; Andreetta F; Antozzi C; Simoncini O; Confalonieri P; Labeit S; Cornelio F; Mantegazza R
    Ann N Y Acad Sci; 1998 May; 841():538-41. PubMed ID: 9668290
    [No Abstract]   [Full Text] [Related]  

  • 15. Autoantibody profile and clinical characteristics in a cohort of Chinese adult myasthenia gravis patients.
    Hong Y; Li HF; Skeie GO; Romi F; Hao HJ; Zhang X; Gao X; Owe JF; Gilhus NE
    J Neuroimmunol; 2016 Sep; 298():51-7. PubMed ID: 27609275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenesis of myositis and myasthenia associated with titin and ryanodine receptor antibodies.
    Skeie GO; Romi F; Aarli JA; Bentsen PT; Gilhus NE
    Ann N Y Acad Sci; 2003 Sep; 998():343-50. PubMed ID: 14592894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Striational antibodies in myasthenia gravis: reactivity and possible clinical significance.
    Romi F; Skeie GO; Gilhus NE; Aarli JA
    Arch Neurol; 2005 Mar; 62(3):442-6. PubMed ID: 15767509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paraneoplastic myasthenia gravis: immunological and clinical aspects.
    Skeie GO; Romi F
    Eur J Neurol; 2008 Oct; 15(10):1029-33. PubMed ID: 18717725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The significance of titin antibodies in myasthenia gravis--correlation with thymoma and severity of myasthenia gravis.
    Chen XJ; Qiao J; Xiao BG; Lu CZ
    J Neurol; 2004 Aug; 251(8):1006-11. PubMed ID: 15316806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ryanodine receptor autoantibodies in myasthenia gravis patients with a thymoma.
    Mygland A; Tysnes OB; Matre R; Volpe P; Aarli JA; Gilhus NE
    Ann Neurol; 1992 Oct; 32(4):589-91. PubMed ID: 1333745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.